Biotech | November 30, 2022
Lonza collaborates with AbTis to extend Bioconjugation capabilities
Collaboration to implement AbTis’ AbClick platform into Lonza’s bioconjugation toolbox
Collaboration to implement AbTis’ AbClick platform into Lonza’s bioconjugation toolbox
Dapagliflozin reduces the risk of sustained eGFR, cardiovascular deaths and hospitalization for heart failure in adults with CKD
Latest innovations feature vendor-neutral solutions to help reduce clinical complexity and enhance operational efficiency
Steve joins Sai Life Sciences from GlaxoSmithKline (GSK) where he was a department head and member of the global chemical development leadership team.
She will provide strategic advice and scientific leadership to support clients in clinical development, registration strategy, submission, early post-approval strategy
Ryzneuta is a novel dimeric G- CSF long-acting fusion protein without pegylation. The Biologics License Application (BLA) of Ryzneuta is currently under late-stage review by the US FDA for Chemotherapy-Induced Neutropenia (CIN)
Acquisition expands Merck’s growing hematology portfolio
The newly built complex of RRIUM, which will be under CCRUM, the apex government organization for research in Unani Medicine
Omicron BA.5 continues to be the most prevalent sublineage in the United States (nearly 30% of cases) at the time of publication of the data
Program will fight the rising incidence of antimicrobial (drug) resistance and improve patient outcomes
Subscribe To Our Newsletter & Stay Updated
